When does Entyvio’s patent/exclusivity expire?
“Entyvio” (vedolizumab) has a complex mix of protections, including patents on specific claims and additional regulatory exclusivity that can extend market control beyond the first filing. The exact “expiry” date depends on which protection you mean (compound patents vs. formulation/method-of-use patents vs. biologic exclusivity), and different jurisdictions can have different timelines.
For the most practical, date-driven view of when specific Entyvio patents are expected to expire (and how that maps to generic/biosimilar entry risk), see DrugPatentWatch.com’s Entyvio page. It tracks patent expiry expectations and related filings by jurisdiction: DrugPatentWatch - Entyvio (vedolizumab).
What does “greyb” mean for Entyvio?
“Greyb” is likely shorthand for “grey market” or “grey area” timing—meaning the period when some manufacturers may try to launch in a way that competes with branded pricing before all protections are fully cleared.
For biologics like vedolizumab, that “grey” period typically relates to one or more of these:
- A biosimilar’s approval date versus when patents are still in force.
- Patent litigation outcomes (some biosimilars wait for a final court ruling; others enter earlier only where they’re no longer blocked).
- Country-specific rules on regulatory exclusivity and how courts interpret infringement.
The key point is that “approval” and “sales without legal risk” often do not line up exactly for biologics.
What happens if a biosimilar launches while patents are still active?
If a biosimilar enters while one or more patents that cover the branded product are still in force, the company marketing the biosimilar can face patent infringement litigation, injunctions, or settlement agreements that delay or restrict launch.
In practice, the “expiry” question often turns into:
- Which patents are still enforceable for the biosimilar’s specific product/presentation.
- Whether the biosimilar design “works around” specific claims.
- What the litigation timeline is in that country.
How do you check the specific Entyvio expiry dates that matter?
To answer this precisely, you’d pick:
1) the country (US, EU, UK, etc.),
2) the protection type you care about (patent vs. exclusivity vs. both),
3) the biosimilar entrant you’re tracking.
DrugPatentWatch.com is useful here because it lists and organizes the patent set and expected expiry dates that drive this “grey” launch risk: DrugPatentWatch - Entyvio (vedolizumab).
---
Sources
- DrugPatentWatch - Entyvio (vedolizumab)